New Clinical Advances: Insulin Delivery Type 2 Diabetes ORMD 0801 – INVESTIGATIONAL ORAL INSULIN CAPSULE FOR T2DM
Diabetes is a chronic condition characterized by hyperglycemia, or elevated blood glucose levels. If left untreated, diabetes may lead to complications such as cardiovascular disease, chronic renal failure, retinopathy and amputations.
Type 2 diabetes (T2DM) is a progressive disease characterized by impaired ß cell function and insulin resistance. There are over 340 million type 2 diabetics worldwide with an economic burden of close to half a trillion dollars annually.
Orally administered insulin should bring with it enhanced patient compliance. In addition, intestinally absorbed-oral insulin actually mimics insulin’s natural location and gradients in the body by first passing through the liver before entering the bloodstream.
Oramed’s investigational oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and delaying or even eliminating late-stage complications. (source: https://www.oramed.com/pipeline/ormd-0801-type-2/)
Metabolic Research Institute Inc. (“MRI”) in West Palm Beach, Florida is currently recruiting adult volunteers to participate in this study. For more information, please call Metabolic Research at (561) 802-3060 or visit our website: https://www.metabolic-institute.com/dm2study/
About Metabolic Research Institute Inc.
Metabolic Research Institute, Inc. (“MRI”), is a private Clinical Research Company located at 1515 North Flagler Drive, Suite 440, West Palm Beach Florida 33401. Unless otherwise noted, all study-related appointments for qualified clinical participants in any MRI research trial will take place at this address.
Metabolic Research Institute’s clinical trials are designed to add to medical knowledge related to the treatment and prevention of diseases or conditions, whether it’s diabetes, high blood pressure, heart disease, high cholesterol, or a variety of other health issues.
This symposium will explore new guidelines and provide updates in the management of diabetes, thyroid and other endocrinologic disorders, and will introduce practical approaches to providing optimal patient care in these areas.
Registration is free…reservations required Saturday September 28, 2019 | 7:00 AM – 5:00 PM
The intended audience for this conference includes primary care physicians and related medical professionals who are seeking to increase their understanding of diabetes, thyroid disease and other endocrine disorders.
Seminar topics to be covered will include: • Diabetes and CVD • Practical Approaches to Insulin Therapy • Diabetes Technology Update • Hashimoto’s Disease • Osteoporosis • Thyroid Nodules • Obesity Management • Hypogonadism
Yesterday, Colorado governor Jared Polis signed into law a measure that will cap total monthly insurance co-pays for insulin at $100. All insurers in the state will have to comply with the new regulation by January 1st, 2020.
The measure caps out-of-pocket costs for a 30-day supply of insulin at $100 for Coloradans with insurance. However, it does not provide a similar cap for out-of-pocket insulin costs for those in the state who lack insurance, nor does it cap out-of-pocket costs for other diabetes supplies.
The legislation also requires the Colorado Department of Law to investigate insulin pricing practices by pharmaceutical companies, pharmacy-benefit managers (PBMs), and insurers, and generate a report that will be made available to the public by November 1st, 2020.
The legislation does not block insurers or PBMs from offering monthly insulin copay caps lower than $100. Such a carve-out may prove important in the future, as insurers and PBMs have been under intense political pressure to cap out-of-pocket insulin costs. Recently, Cigna and Express Scripts rolled out a program in which participating customers will pay no more than $25 for a 30-day insulin supply.
The legislation’s passage was cheered by diabetes and disability advocates, including the American Diabetes Association.
The Colorado BioScience Association, CVS Health, United HealthCare, and Pharmaceutical Research and Manufacturers of America (PhRMA) all opposed the legislation, according to a regional policy report. Reasons to impose the measure included that it has the potential to drive up insurance plan costs and that it is being administered by the Colorado Department of Law, rather than state insurance or health care policy regulators.
This appears to be the first state law aimed specifically at capping insulin out-of-pocket costs. Many other states are considering bills aimed at reducing the economic burden of the insulin pricing crisis, according to a Healthline report.
If your child is between the ages of 12 – 17 and struggles with eczema (atopic dermatitis), you may be interested in a new research study in your local area. The study is for an investigational topical cream, applied twice daily for mild to moderate eczema.
The study lasts about 14 months, and there is no cost to participate. You will also be compensated for your time and travel to attend study visits.
Metabolic Research Institute, Inc. (“MRI”), is a private Clinical Research Company located at 1515 North Flagler Drive, Suite 440, West Palm Beach Florida 33401. Unless otherwise noted, all study-related appointments for qualified clinical participants in any MRI research trial will take place at this address.
Metabolic Research Institute’s clinical trials are designed to add to medical knowledge related to the treatment, diagnosis, and prevention of diseases or conditions, whether it’s diabetes, high blood pressure, heart disease, high cholesterol, or a variety of other health issues.
CURRENTLY USING AN INSULIN PUMP? CONSIDER THE PRONTO-Pump-2 STUDY
You may be eligible for a clinical research study that will test if an investigational ‘ultra-rapid’ insulin can offer better blood glucose control for people with type 1 diabetes who use an insulin pump than currently available rapid-acting insulins.
If you meet the study criteria you will need to attend regular study visits and will receive all study-related visits, lab tests, assessments, as well as study insulins and supplies at no cost. Travel reimbursement will also be available.
We are looking for participants who: • Are at least 18 years old • Are diagnosed with type 1 diabetes and have been using insulin continuously for at least 12 months • Have been using an insulin pump with rapid-acting insulin for at least 6 months • Have been using the MiniMed 530G (US), Paradigm Revel (US), MiniMed 630G (US and Canada), MiniMed 640G or Paradigm Veo (outside of the US and Canada) insulin pump for at least the past 90 days
Clinical studies are an integral part of clinical research and are at the heart of all advances in modern medicine. Our mission at the Metabolic Research Institute is to provide our patients and sponsors with the highest quality of diabetes clinical research available in today’s medical professional environment. We are committed to delivering efficient and timely research data, while focusing on strict adherence to protocol guidelines.
Metabolic Research Institute, Inc. (“MRI”), is a private Clinical Research Company located at 1515 North Flagler Drive, Suite 440, West Palm Beach Florida 33401. Unless otherwise noted, all study-related appointments for qualified clinical participants in any MRI research trial will take place at this add
Diabetes is a chronic condition characterized by hyperglycemia, or elevated blood glucose levels. If left untreated, diabetes may lead to complications such as cardiovascular disease, chronic renal failure, retinopathy and amputations.
